Investment case
Liminatus Pharma, Inc.
LIMN · 2 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 2 macro, policy, and market developments to Liminatus Pharma, Inc. since 2026-08-18. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for LIMN yet, so no modelled value is shown. The LIMN valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run LIMN on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Liminatus Pharma, Inc. Announces 1-for-50 Reverse Stock Split
Direct impact on share structure and market perception; often a precursor to delisting or continued share price weakness.
· Moves perceived risk profile of the company, liquidity of shares, market sentiment towards micro cap stocks
- Open question
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Direct regulatory compliance, investor sentiment, and potential for future capital raises.
· Moves risk premium for micro cap stocks, liquidity discount, ability to raise capital
What changed, by assumption
- 2026-08-18Liminatus Pharma, Inc. Announces 1-for-50 Reverse Stock Split
- 2026-09-29Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-18 | Net debt | Bearish | Liability-management transactions often reduce gross debt or push maturities out. | 0.70 |
| 2026-08-18 | Interest expense | Bearish | Tender/exchange extends maturity profile and typically lowers near-term interest expense. | 0.70 |
| 2026-07-06 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-07-06 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-07-06 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule | mixed | 1-3m | 0.60 |
| 2026-08-18 | Liminatus Pharma, Inc. Announces 1-for-50 Reverse Stock Split | Bearish | 1-3m | 0.70 |